Diese Seite wurde automatisch übersetzt und die Genauigkeit der Übersetzung wird nicht garantiert. Bitte wende dich an die englische Version für einen Quelltext.

Image-Guided Platform-Assisted Sentinel Lymph Node Retrieval in Early Gastric Cancer

17. September 2026 aktualisiert von: JunZhang, Beijing Friendship Hospital

Image-Guided Platform-Assisted Intraoperative and Postoperative Sentinel Lymph Node Retrieval in Early Gastric Cancer: A Prospective Randomized Controlled Trial

This prospective, single-center, randomized controlled trial aims to evaluate the clinical effectiveness of an Image-Guided Platform assisted by a deep learning model for sentinel lymph node (SLN) retrieval in patients with early gastric cancer undergoing laparoscopic-endoscopic cooperative surgery combined with sentinel lymph node navigation surgery (LECS-SNNS).

A total of 36 eligible participants will be randomly assigned in a 1:1 ratio to either the Image-Guided Platform group or the Traditional Palpation group. Both groups will undergo standardized indocyanine green fluorescence-guided sentinel lymphatic basin dissection and initial retrieval of fluorescent sentinel lymph nodes. In the experimental group, the remaining sentinel lymphatic basin (SLB) tissue will be examined using the Image-Guided Platform, which integrates radiographic and optical imaging with a deep learning model to identify and localize suspected lymph nodes. In the control group, LN retrieval will be performed using traditional visual inspection and palpation.

The primary objective is to determine whether Image-Guided Platform-assisted LN retrieval increases the total number of SLNs retrieved intraoperatively compared with Traditional Palpation. Secondary objectives include assessment of LN retrieval efficiency, pathological findings, additional LN identification during permanent pathological examination, concordance between intraoperative frozen-section and permanent pathological examination, and other procedural, pathological, technical, and clinical outcomes relevant to the feasibility and performance of the Image-Guided Platform and deep learning model.

Studienübersicht

Detaillierte Beschreibung

Sentinel lymph node navigation surgery provides an individualized approach to lymph node assessment in patients with early gastric cancer. However, the identification and retrieval of sentinel lymph nodes (SLNs) from resected sentinel lymphatic basin (SLB) tissue remain largely dependent on visual inspection and manual palpation by experienced physicians. This process can be time-consuming and operator-dependent and may result in missed lymph nodes (LNs), particularly small or visually inconspicuous nodes.

This study is a single-center, prospective, randomized, superiority-controlled trial designed to evaluate an Image-Guided Platform assisted by a deep learning model for intraoperative and postoperative SLN retrieval in patients with early gastric cancer undergoing laparoscopic-endoscopic cooperative surgery combined with sentinel lymph node navigation surgery (LECS-SNNS). Eligible participants will be randomly assigned in a 1:1 ratio to either the Image-Guided Platform group or the Traditional Palpation group. Randomization will be performed using a computer-generated random sequence with allocation concealment.

All participants will undergo a standardized LECS-SNNS procedure. Indocyanine green (ICG) will be injected endoscopically around the gastric lesion for near-infrared fluorescence lymphatic mapping. Fluorescent SLBs will be identified and resected en bloc. Fluorescent SLNs identified by visual inspection and fluorescence imaging will initially be retrieved and designated as SBNs. In the Image-Guided Platform group, the remaining SLB tissue will be placed on the Image-Guided Platform for radiographic and optical imaging. The acquired images will be analyzed using a deep learning model to identify and localize suspected LNs. Physicians will subsequently retrieve suspected LNs according to the image-guided and model-generated localization results. After image-guided LN retrieval, supplementary visual inspection and manual palpation will be performed to identify any additional LNs when appropriate. In the Traditional Palpation group, the remaining SLB tissue will be systematically examined by experienced physicians using standardized dissection, visual inspection, and manual palpation to identify and retrieve suspected LNs without image-guided or deep learning-assisted localization.

All retrieved SLNs will undergo intraoperative frozen-section pathological examination according to standardized institutional procedures. Permanent pathological examination will subsequently be performed to confirm the pathological findings and to identify any additional LNs that were not retrieved during the intraoperative LN retrieval process. This approach will allow assessment of retrieved LNs, additional LNs identified during permanent pathological examination, and the overall LN harvest from the SLB specimen.

Data Collection and Assessments

Study data will include a broad range of demographic, clinical, diagnostic, surgical, pathological, technical, imaging-related, and perioperative information relevant to early gastric cancer, sentinel lymph node navigation surgery, LN retrieval, and pathological assessment. Data collection may include baseline demographic and clinical characteristics; medical and treatment history; preoperative laboratory, endoscopic, imaging, and clinical staging information; tumor-related characteristics; intraoperative and surgical variables; fluorescence mapping and SLB characteristics; LN retrieval and specimen-handling information; Image-Guided Platform-related parameters; radiographic and optical image-related parameters; deep learning model-related parameters; intraoperative frozen-section findings; permanent pathological findings; LN-related characteristics; perioperative recovery and safety information; and other clinically relevant variables collected according to the study protocol and case report forms. Derived variables, composite variables, subgroup classifications, technical performance measures, image- or specimen-level parameters, and exploratory clinical or pathological variables may also be generated from the collected data according to prespecified or exploratory statistical analyses. The collected information will be used to compare the effectiveness, efficiency, and diagnostic performance of Image-Guided Platform-assisted LN retrieval and Traditional Palpation, and to explore factors potentially associated with LN retrieval, total LN harvest, pathological assessment, technical performance, and other relevant clinical outcomes.

Studientyp

Interventionell

Einschreibung (Geschätzt)

36

Phase

  • Unzutreffend

Kontakte und Standorte

Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.

Studienkontakt

Studienorte

      • Beijing, China
        • Rekrutierung
        • Beijing Friendship Hospital, Capital Medical University
        • Kontakt:

Teilnahmekriterien

Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.

Zulassungskriterien

Studienberechtigtes Alter

18 Jahre bis 80 Jahre (Erwachsene, Älterer Erwachsener)

Akzeptiert gesunde Freiwillige

Nein

Studienberechtigte Geschlechter

Alle

Beschreibung

Inclusion Criteria:

  1. Age between 18 and 80 years, inclusive.
  2. Eastern Cooperative Oncology Group (ECOG) performance status of 0-2 and considered able to tolerate surgery and anesthesia.
  3. Histologically confirmed gastric adenocarcinoma based on preoperative endoscopic biopsy.
  4. Clinical stage cT1N0M0 based on multidisciplinary evaluation and appropriate preoperative examinations, including endoscopy and imaging, or patients after non-curative endoscopic submucosal dissection (ESD) who are considered appropriate candidates for further surgical treatment.
  5. Adequate hepatic, renal, cardiac, pulmonary, and bone marrow function to tolerate the planned surgical and perioperative management.
  6. Considered clinically suitable for laparoscopic-endoscopic cooperative surgery combined with sentinel lymph node navigation surgery (LECS-SNNS).
  7. Able to understand the study procedures and provide written informed consent voluntarily.

Exclusion Criteria:

  1. Patients who meet the absolute indications for endoscopic submucosal dissection according to the applicable Chinese gastric cancer treatment guidelines.
  2. Contraindications to the use of the lymphatic tracer or to endoscopic examination.
  3. Unable to undergo ESD or failure of ESD treatment.
  4. Inability to determine the extent of tracer staining or fluorescence mapping.
  5. Contraindications to surgery, including clinically significant coagulation disorders or severe cardiopulmonary dysfunction.
  6. Previous gastrointestinal surgery, chemotherapy, or radiotherapy.
  7. Preoperative imaging indicating bulky, conglomerated, or markedly enlarged metastatic lymph nodes.
  8. Concurrent malignancy involving another organ system, or intraoperative confirmation of metastatic gastric cancer or a non-gastric primary malignancy.
  9. Pregnancy or breastfeeding.
  10. Psychiatric disorders, cognitive impairment, or other conditions that impair the ability to provide informed consent or comply with study procedures.
  11. Any other condition that, in the investigator's judgment, makes the individual unsuitable for participation in the study.

Studienplan

Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.

Wie ist die Studie aufgebaut?

Designdetails

  • Hauptzweck: Sonstiges
  • Zuteilung: Zufällig
  • Interventionsmodell: Parallele Zuordnung
  • Maskierung: Doppelt

Waffen und Interventionen

Teilnehmergruppe / Arm
Intervention / Behandlung
Experimental: Image-Guided Platform

Participants in this arm will undergo standardized LECS-SNNS with indocyanine green (ICG) fluorescence mapping. Following initial retrieval of fluorescent SLNs, the remaining SLB tissue will be placed on the Image-Guided Platform for radiographic and optical imaging. The acquired images will be analyzed using a deep learning model to identify and localize suspected LNs. Physicians will subsequently retrieve suspected LNs according to the image-guided and model-generated localization results. Supplementary visual inspection and manual palpation will then be performed when appropriate to identify any additional LNs.

The Image-Guided Retrieval Specimen Platform is an ex vivo LN retrieval system integrating radiographic imaging, optical imaging, and deep learning-based image analysis. Resected SLB tissue is placed on the platform for image acquisition. The acquired images are analyzed using a deep learning model to identify and localize regions suspected of containing LNs. Physicians subsequently retrieve suspected LNs according to the image-guided and model-generated localization results. All retrieved specimens are submitted for standardized pathological examination.

Aktiver Komparator: Traditional Palpation

Participants in this arm will undergo the same standardized LECS-SNNS and ICG fluorescence mapping procedure. Following initial retrieval of fluorescent SLNs, the remaining SLB tissue will be systematically examined by experienced physicians using standardized dissection, visual inspection, and manual palpation to identify and retrieve suspected LNs without image-guided or deep learning-assisted localization.

The residual SLB tissue will be systematically examined by experienced physicians using standardized dissection, visual inspection, and manual palpation to identify and retrieve suspected LNs. No Image-Guided Platform or deep learning-assisted localization will be used.

Was misst die Studie?

Primäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Total Number of Sentinel Lymph Nodes Retrieved Intraoperatively From the Sentinel Lymphatic Basin Specimen
Zeitfenster: During the operation, before completion of intraoperative frozen-section pathological assessment

The primary outcome is the per-participant total number of SLNs retrieved from the resected SLB specimen and submitted for intraoperative frozen-section pathological examination. The total number is defined as the sum of fluorescent SLNs identified during initial fluorescence-guided retrieval (SBNs) and additional non-fluorescent LNs retrieved from the residual SLB tissue during subsequent LN retrieval (BNs).

The total number of intraoperatively retrieved SLNs will be compared between the Image-Guided Platform group and the Traditional Palpation group.

During the operation, before completion of intraoperative frozen-section pathological assessment

Sekundäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Number of Fluorescent Specimens Not Pathologically Confirmed as Lymph Nodes
Zeitfenster: From the operation through completion of permanent pathological examination, within 30 days after surgery

The number of ICG-fluorescent specimens initially retrieved as fluorescent SLNs but not subsequently confirmed as actual LNs by pathological examination will be recorded for each participant and compared between the two groups.

From the operation through completion of permanent pathological examination, within 30 days after surgery
Number of Occult Lymph Nodes Identified During Permanent Pathological Examination
Zeitfenster: From the operation through completion of permanent pathological examination, within 30 days after surgery

The number of additional LNs identified during permanent pathological examination of the residual SLB tissue after completion of intraoperative LN retrieval will be recorded for each participant. These LNs correspond to occult lymph nodes (OBNs) that were not identified during intraoperative LN retrieval.

From the operation through completion of permanent pathological examination, within 30 days after surgery
Total Lymph Node Harvest From the Sentinel Lymphatic Basin Specimen
Zeitfenster: From the operation through completion of permanent pathological examination, within 30 days after surgery

The total LN harvest from the resected SLB specimen will be recorded for each participant. Total LN harvest is defined as the sum of LNs retrieved during intraoperative LN retrieval and additional LNs identified during permanent pathological examination.

From the operation through completion of permanent pathological examination, within 30 days after surgery
Proportion of Participants With Occult Lymph Nodes Identified During Permanent Pathological Examination
Zeitfenster: From the operation through completion of permanent pathological examination, within 30 days after surgery

The proportion of participants in whom at least one occult LN is identified during permanent pathological examination after completion of intraoperative LN retrieval will be assessed.

From the operation through completion of permanent pathological examination, within 30 days after surgery
Lymph Node-Level Concordance Rate Between Intraoperative Frozen-Section and Permanent Pathological Examination
Zeitfenster: From the operation through completion of permanent pathological examination, within 30 days after surgery

For SLNs examined by both methods, the concordance rate will be calculated as the number of SLNs with concordant pathological classifications between intraoperative frozen-section and permanent pathological examination divided by the total number of SLNs examined by both methods, expressed as a percentage.

From the operation through completion of permanent pathological examination, within 30 days after surgery
Lymph Node Retrieval Time
Zeitfenster: During LN retrieval on the day of surgery

The time required to complete LN retrieval from the residual SLB tissue will be recorded for each participant and reported in minutes.

During LN retrieval on the day of surgery
Intraoperative Sentinel Lymph Node Retrieval and Frozen-Section Pathology Workflow Time
Zeitfenster: During the operation on the day of surgery

The total workflow time will be recorded for each participant. Timing will begin when the residual SLB tissue, following initial retrieval of fluorescent SLNs, is transferred for further LN retrieval and pathological processing and will end when the intraoperative frozen-section pathology report is issued. The outcome will be reported in minutes.

During the operation on the day of surgery
Number of Additional Lymph Nodes Retrieved by Supplementary Manual Palpation After Image-Guided Retrieval
Zeitfenster: During LN retrieval on the day of surgery

In the Image-Guided Platform group, the number of additional LNs retrieved by supplementary visual inspection and manual palpation after completion of image-guided LN retrieval will be recorded. This outcome reflects LNs that were not initially identified during image-guided retrieval but were subsequently detected by supplementary manual palpation.

During LN retrieval on the day of surgery
Number of Lymph Nodes Retrieved With the Image-Guided Platform
Zeitfenster: During LN retrieval on the day of surgery

In the Image-Guided Platform group, the number of suspected LNs identified using the platform and subsequently retrieved for pathological examination will be recorded.

During LN retrieval on the day of surgery
Pathological Confirmation Rate of Suspected Lymph Nodes Retrieved From Residual Sentinel Lymphatic Basin Tissue
Zeitfenster: From LN retrieval through completion of permanent pathological examination, within 30 days after surgery

The pathological confirmation rate will be assessed separately according to the LN retrieval method used for the residual SLB tissue after initial fluorescent SLN retrieval. For each retrieval method, the pathological confirmation rate will be calculated as the number of retrieved specimens pathologically confirmed as actual LNs divided by the total number of specimens retrieved as suspected LNs, expressed as a percentage.

From LN retrieval through completion of permanent pathological examination, within 30 days after surgery
Lymph Node Detection Rate of the Image-Guided Platform
Zeitfenster: From specimen imaging through completion of permanent pathological examination, within 30 days after surgery

The LN detection rate of the Image-Guided Platform will be calculated as the number of pathologically confirmed actual LNs correctly identified by the Image-Guided Platform divided by the total number of actual LNs ultimately identified from the residual SLB tissue examined by the platform, expressed as a percentage. The denominator will include pathologically confirmed LNs retrieved with the Image-Guided Platform, additional LNs retrieved by supplementary manual palpation, and additional LNs subsequently identified during permanent pathological examination of the residual SLB tissue.

From specimen imaging through completion of permanent pathological examination, within 30 days after surgery

Mitarbeiter und Ermittler

Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.

Studienaufzeichnungsdaten

Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.

Haupttermine studieren

Studienbeginn (Tatsächlich)

14. August 2026

Primärer Abschluss (Geschätzt)

14. August 2027

Studienabschluss (Geschätzt)

14. August 2027

Studienanmeldedaten

Zuerst eingereicht

17. September 2026

Zuerst eingereicht, das die QC-Kriterien erfüllt hat

17. September 2026

Zuerst gepostet (Tatsächlich)

22. September 2026

Studienaufzeichnungsaktualisierungen

Letztes Update gepostet (Tatsächlich)

22. September 2026

Letztes eingereichtes Update, das die QC-Kriterien erfüllt

17. September 2026

Zuletzt verifiziert

1. August 2026

Mehr Informationen

Begriffe im Zusammenhang mit dieser Studie

Plan für individuelle Teilnehmerdaten (IPD)

Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?

NEIN

Arzneimittel- und Geräteinformationen, Studienunterlagen

Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt

Nein

Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt

Nein

Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .

Abonnieren